Build status - In Progress
Found 10 Colon Cancer trials
A listing of Colon Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Featured study
This study investigates colon cancer treatment after surgery. The purpose is to understand how chemotherapy affects patients with remaining disease.The focus is on evaluating the effectiveness of chemotherapy regimens in patients with detectable cancer DNA after surgery.Who can participate: Eligibility criteria are yet to be determined.Study details: Participants will receive …
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
The purpose of this research study is to collect blood samples and applicable medical history from subjects diagnosed with hereditary colon cancer syndromes like FAP, Lynch Syndrome and MYK-associated polyposis and their family members. These samples will be used to evaluate the ability of a blood test to provide early …
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
Please choose between Voice or SMS based delivery of verification code
or